☆ 4.7 Article

Real-World experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)

JOURNAL OF AFFECTIVE DISORDERS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Clinical Neurology

Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis

Nicolas A. Nunez et al.

Summary: This study compared the efficacy and discontinuation of augmentation agents in adult patients with treatment-resistant depression through a systematic review and network meta-analyses. The findings suggest that certain adjunctive atypical antipsychotics, thyroid hormones, dopamine compounds, and lithium are superior in terms of efficacy. However, ziprasidone, mirtazapine, and cariprazine had higher discontinuation rates. Further research and head-to-head studies are needed to strengthen treatment options for treatment-resistant depression.

JOURNAL OF AFFECTIVE DISORDERS (2022)

添加到收藏夹

Review Psychiatry

The abuse liability of ketamine: A scoping review of preclinical and clinical studies

Tuyen T. Le et al.

Summary: This scoping review examines the abuse liability of ketamine and its enantiomers. Preclinical studies suggest that (R,S)-ketamine and (S)-ketamine have a higher risk for abuse, while (R)-ketamine shows minimal abuse liability at doses relevant for antidepressant effects. Limited clinical studies indicate that ketamine administration in professionally controlled settings did not result in misuse, dependence, diversion, or gateway activity in patients with treatment-resistant depression (TRD).

JOURNAL OF PSYCHIATRIC RESEARCH (2022)

添加到收藏夹

Review Psychiatry

Adverse Effects of Esketamine for the Treatment of Major Depression Disorder: Findings from Randomized Controlled Trials

Siyuan Yang et al.

Summary: In the treatment of Major Depression Disorder, Esketamine carries a certain risk of adverse effects, including nausea, dissociation, dizziness, vertigo, hypoesthesia, sedation, and paresthesia.

PSYCHIATRIC QUARTERLY (2022)

添加到收藏夹

Review Neurosciences

Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment

Jason Ng et al.

Summary: This study examines the antidepressant effects of ketamine in adults with treatment-resistant depression and the potential urological toxicity associated with chronic ketamine use. High-frequency ketamine abuse is linked to bladder inflammation.

PSYCHOPHARMACOLOGY (2021)

添加到收藏夹

Review Clinical Neurology

Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression

Filippo Cantu et al.

Summary: Studies have shown that aripiprazole and quetiapine may be beneficial in the treatment of TRD. RCTs on these drugs support their use in TRD, especially when comorbid anxiety or insomnia are present. However, larger and more homogenous RCTs are needed to improve the therapeutic outcome for patients with TRD.

JOURNAL OF AFFECTIVE DISORDERS (2021)

添加到收藏夹

Article Psychiatry

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

Roger S. McIntyre et al.

Summary: Replicated international studies have highlighted the human and societal costs of major depressive disorder, with monoamine-based antidepressants proving effective but many patients failing to fully recover. Ketamine and esketamine offer novel pharmacological treatments for treatment-resistant depression, but questions remain about their safety and effectiveness. International experts provide guidance on the use of these agents, while discussing areas of consensus and future research directions.

AMERICAN JOURNAL OF PSYCHIATRY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Enrico Capuzzi et al.

Summary: For long-term efficacy, esketamine treatment for treatment-resistant depression shows some stability in preventing relapse, but there is debate regarding its long-term antidepressant effects after discontinuation.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Clinical Neurology

Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review

Jolien K. E. Veraart et al.

Summary: Ketamine may interact with certain drugs, such as benzodiazepines and clozapine. Literature suggests that benzodiazepines and lamotrigine may reduce the efficacy of ketamine treatment.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)

添加到收藏夹

Review Neurosciences

Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Giovanni Martinotti et al.

Summary: The obsessive-compulsive spectrum encompasses disorders with similar core features, such as obsessive thoughts, compulsive behaviors, and anxiety. Ketamine has shown remarkable results in treating depression, PTSD, and OCD, but its efficacy in SUD and ED remains uncertain. Further studies are needed to clarify its potential in these conditions.

BRAIN SCIENCES (2021)

添加到收藏夹

Article Psychology, Clinical

Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies

Ibrahim Turkoz et al.

Summary: For patients with treatment-resistant depression who did not show response within the first week of treatment, a combination of esketamine nasal spray and an oral antidepressant (ESK + AD) can significantly increase response rates at day 28, providing more benefits to patients.

JOURNAL OF CLINICAL PSYCHIATRY (2021)

添加到收藏夹

Article Psychology, Clinical

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

Maryia Zhdanava et al.

Summary: This study evaluated the prevalence and burden of treatment-resistant depression (TRD) in the United States, finding that TRD accounted for a significant proportion of the burden of medication-treated major depressive disorder (MDD). The study highlighted the disproportionate health care costs and unemployment associated with TRD, suggesting potential economic and societal gains with effective management.

JOURNAL OF CLINICAL PSYCHIATRY (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3

Rachel Ochs-Ross et al.

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)

添加到收藏夹

Article Clinical Neurology

Rapid effects of S-ketamine on the morphology of hippocampal astrocytes and BDNF serum levels in a sex-dependent manner

Maryam Ardalan et al.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2020)

添加到收藏夹

Review Psychiatry

Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives

Cheolmin Shin et al.

PSYCHIATRY INVESTIGATION (2020)

添加到收藏夹

Review Chemistry, Medicinal

Pharmacological Treatments for Patients with Treatment-Resistant Depression

Valerie L. Ruberto et al.

PHARMACEUTICALS (2020)

添加到收藏夹

Article Psychology, Clinical

Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)

Ewa Wajs et al.

JOURNAL OF CLINICAL PSYCHIATRY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review

Mohammed S. Salahudeen et al.

THERAPEUTIC ADVANCES IN DRUG SAFETY (2020)

添加到收藏夹

Article Psychiatry

Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study

Vanina Popova et al.

AMERICAN JOURNAL OF PSYCHIATRY (2019)

添加到收藏夹

Review Clinical Neurology

Esketamine for treatment resistant depression

Jennifer Swainson et al.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)

添加到收藏夹

Article Clinical Neurology

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

Maggie Fedgchin et al.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)

添加到收藏夹

Article Psychiatry

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial

Ella J. Daly et al.

JAMA PSYCHIATRY (2019)

添加到收藏夹

Article Psychiatry

Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial

Sanne Y. Smith-Apeldoorn et al.

BMC PSYCHIATRY (2019)

添加到收藏夹

Article Psychiatry

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression A Randomized Clinical Trial

Ella J. Daly et al.

JAMA PSYCHIATRY (2018)

添加到收藏夹

Editorial Material Neurosciences

Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism

Lily R. Aleksandrova et al.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2017)

添加到收藏夹

Article Psychology, Clinical

Assessing the Risk Factors for Difficult-to-Treat Depression and Treatment-Resistant Depression

Bradley Gaynes

JOURNAL OF CLINICAL PSYCHIATRY (2016)

添加到收藏夹

Article Clinical Neurology

Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression

Yong-Ku Kim et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)

添加到收藏夹

Review Clinical Neurology

Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach

Roger S. McIntyre et al.

JOURNAL OF AFFECTIVE DISORDERS (2014)

添加到收藏夹

Article Neurosciences

Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

Carlos A. Zarate et al.

BIOLOGICAL PSYCHIATRY (2012)

添加到收藏夹

Article Neurosciences

Chronic ketamine use increases serum levels of brain-derived neurotrophic factor

Valerio Ricci et al.

PSYCHOPHARMACOLOGY (2011)

添加到收藏夹

Article Psychology, Clinical

Rapid Resolution of Suicidal Ideation After a Single Infusion of an N-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder

Nancy DiazGranados et al.

JOURNAL OF CLINICAL PSYCHIATRY (2010)

添加到收藏夹

Article Psychiatry

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Carlos A. Zarate et al.

ARCHIVES OF GENERAL PSYCHIATRY (2006)

添加到收藏夹

Article Clinical Neurology

Moderate and severe depression gradations for the Montgomery-Asberg Depression Rating Scale

MJ Müller et al.

JOURNAL OF AFFECTIVE DISORDERS (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.